Major Shareholder Makes Bold Move with iTeos Therapeutics Stock

New insider activity at iTeos Therapeutics ( (ITOS) ) has taken place on May 17, 2025.

Ecor1 Capital, LLC, a significant shareholder, has made a substantial investment in iTeos Therapeutics by purchasing 4,958,978 shares. This acquisition is valued at $38,676,437, indicating a strong vote of confidence in the company’s potential.

Recent Updates on ITOS stock

In the last 24 hours, iTeos Therapeutics experienced significant analyst activity following the termination of its collaboration with GlaxoSmithKline (GSK) on the belrestotug development program. This decision was driven by the failure of the GALAXIES Lung-201 study to meet progression-free survival criteria. Analysts from Wells Fargo, Piper Sandler, Leerink, H.C. Wainwright, and JPMorgan have adjusted their ratings and price targets for iTeos, reflecting the impact of the program’s termination on the company’s prospects. The termination is seen as a strategic shift for iTeos, which is now exploring alternative strategies to enhance shareholder value. Despite the setback, some analysts view the termination positively, awaiting further clarity on iTeos’s future strategy.

Spark’s Take on ITOS Stock

According to Spark, TipRanks’ AI Analyst, ITOS is a Neutral.

iTeos Therapeutics’ overall stock score is primarily impacted by its financial difficulties, including declining profitability and negative cash flow. While technical analysis suggests some potential for upward momentum, the stock’s valuation is a significant drawback due to its negative P/E ratio. The recent termination of a major collaboration adds further uncertainty. Investors should be cautious and consider the company’s ability to improve its financial performance and strategic direction before investing.

To see Spark’s full report on ITOS stock, click here.

More about iTeos Therapeutics

YTD Price Performance: 0.89%

Average Trading Volume: 746,583

Technical Sentiment Signal: Hold

Current Market Cap: $290.9M